HQ: Cambridge, MA, USACEO: John EvansHeadcount: 400+beamtx.com ↗
Funding Summary
Total Funding
$700M+
Latest Valuation
~$1.5B (public market cap)
About
Develops precision genetic medicines using base editing technology that makes single-letter changes to DNA without double-strand breaks. Lead programs in sickle cell disease and oncology.
Products
base-editing-therapeutics
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →